Repligen Corporation $RGEN Stock Holdings Lifted by California State Teachers Retirement System

California State Teachers Retirement System increased its position in Repligen Corporation (NASDAQ:RGEN) by 22.1% during the first quarter, HoldingsChannel reports. The institutional investor owned 61,860 shares of the biotechnology company’s stock after acquiring an additional 11,206 shares during the period. California State Teachers Retirement System’s holdings in Repligen were worth $7,288,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. NewEdge Wealth LLC raised its holdings in Repligen by 5.3% during the fourth quarter. NewEdge Wealth LLC now owns 1,492 shares of the biotechnology company’s stock valued at $244,000 after buying an additional 75 shares in the last quarter. UMB Bank n.a. boosted its stake in shares of Repligen by 13.8% during the 4th quarter. UMB Bank n.a. now owns 758 shares of the biotechnology company’s stock worth $124,000 after acquiring an additional 92 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its stake in shares of Repligen by 0.3% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 36,599 shares of the biotechnology company’s stock worth $4,542,000 after acquiring an additional 100 shares in the last quarter. Coldstream Capital Management Inc. increased its holdings in shares of Repligen by 5.3% during the 4th quarter. Coldstream Capital Management Inc. now owns 1,992 shares of the biotechnology company’s stock valued at $326,000 after acquiring an additional 101 shares during the last quarter. Finally, Itau Unibanco Holding S.A. increased its holdings in shares of Repligen by 38.0% during the 4th quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock valued at $62,000 after acquiring an additional 104 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Insider Transactions at Repligen

In other Repligen news, CFO Jason K. Garland sold 733 shares of the business’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the transaction, the chief financial officer owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. The trade was a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.60% of the company’s stock.

Repligen Price Performance

NASDAQ:RGEN opened at $149.78 on Wednesday. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. The firm has a market cap of $8.45 billion, a PE ratio of 205.18, a price-to-earnings-growth ratio of 2.68 and a beta of 1.03. Repligen Corporation has a 12 month low of $100.99 and a 12 month high of $175.77. The company’s 50-day moving average price is $135.99 and its two-hundred day moving average price is $131.12.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.09. The company had revenue of $204.13 million during the quarter, compared to analyst estimates of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The company’s revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the business posted $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, equities analysts anticipate that Repligen Corporation will post 2.06 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on RGEN shares. Barclays boosted their target price on Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Rothschild & Co Redburn set a $160.00 price target on shares of Repligen and gave the company a “buy” rating in a research report on Friday, April 17th. Citigroup raised shares of Repligen to a “buy” rating in a report on Tuesday, July 7th. Wells Fargo & Company raised their target price on Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a report on Thursday, July 30th. Finally, JPMorgan Chase & Co. increased their target price on shares of Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $166.43.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.